306 related articles for article (PubMed ID: 33427203)
21. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
22. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
Lugtenburg PJ; de Nully Brown P; van der Holt B; D'Amore FA; Koene HR; de Jongh E; Fijnheer R; van Esser JW; Böhmer LH; Pruijt JF; Verhoef GE; Hoogendoorn M; Bilgin MY; Nijland M; van der Burg-de Graauw NC; Oosterveld M; Jie KG; Larsen TS; van der Poel MW; Leijs MB; Silbermann MH; van Marwijk Kooy M; Beeker A; Kersten MJ; Doorduijn JK; Tick LW; Brouwer RE; Lam KH; Burggraaff CN; de Keizer B; Arens AI; de Jong D; Hoekstra OS; Zijlstra-Baalbergen JM
J Clin Oncol; 2020 Oct; 38(29):3377-3387. PubMed ID: 32730183
[TBL] [Abstract][Full Text] [Related]
23. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
24. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
Dorth JA; Prosnitz LR; Broadwater G; Diehl LF; Beaven AW; Coleman RE; Kelsey CR
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):762-7. PubMed ID: 22420972
[TBL] [Abstract][Full Text] [Related]
25. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.
Lee GW; Go SI; Kim SH; Hong J; Kim YR; Oh S; Kim SY; Do YR; Lee H; Lee SI; Bae SH; Oh SY; Song MK; Lee WS; Lee B; Kim JS; Kim MK; Kang HJ; Ahn JS; Yhim HY; Kim HJ; Kim SJ; Kim WS; Suh C;
Leuk Lymphoma; 2015 Apr; 56(4):1020-6. PubMed ID: 25039351
[TBL] [Abstract][Full Text] [Related]
27. B-cell lymphoma of the female breast: comparison of mammography, ultrasound and dynamic MRI.
Zechmann CM; Buchheidt D; Hildenbrand R; Teubner J
Ultraschall Med; 2010 Feb; 31(1):71-3. PubMed ID: 19401980
[No Abstract] [Full Text] [Related]
28. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
30. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathological features of primary cardiac CD5-positive and bcl-2 and C-MYC double expression diffuse large B-cell lymphoma].
Zhang F; Luo DL; Chen Y; Liu J; Luo LQ; He J; Yan JH; Xu J; Luo XL; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2019 Dec; 48(12):951-954. PubMed ID: 31818069
[No Abstract] [Full Text] [Related]
32. [Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases].
Yang H; Lang RG; Liu FF; Wang XF; Jin ZJ; Lü AJ; Wang Y; Fu XL; Fu L
Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):79-84. PubMed ID: 21426801
[TBL] [Abstract][Full Text] [Related]
33. Malignant lymphoma of the vagina successfully treated with rituximab, adryamicin, cyclophosphamide, vincristine sulfate, and prednisolone.
Nasu K; Okamoto M; Nishida M; Takai N; Narahara H
Eur J Gynaecol Oncol; 2012; 33(2):219-22. PubMed ID: 22611969
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
Bittenbring JT; Neumann F; Altmann B; Achenbach M; Reichrath J; Ziepert M; Geisel J; Regitz E; Held G; Pfreundschuh M
J Clin Oncol; 2014 Oct; 32(29):3242-8. PubMed ID: 25135997
[TBL] [Abstract][Full Text] [Related]
35. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
Offner F; Samoilova O; Osmanov E; Eom HS; Topp MS; Raposo J; Pavlov V; Ricci D; Chaturvedi S; Zhu E; van de Velde H; Enny C; Rizo A; Ferhanoglu B
Blood; 2015 Oct; 126(16):1893-901. PubMed ID: 26232170
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
[TBL] [Abstract][Full Text] [Related]
37. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
[TBL] [Abstract][Full Text] [Related]
38. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
[TBL] [Abstract][Full Text] [Related]
39. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
40. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
